The global market for GLP-1 receptor agonist drugs, initially developed for Type 2 diabetes, is on track for explosive growth, projected to more than quadruple by 2034. Valued at $61.89 billion in 2025, the market is expected to surge to $257.12 billion within a decade, driven by accelerating demand for weight-loss and metabolic therapies worldwide.
This significant expansion, forecasted at a compound annual growth rate (CAGR) of 17.14%, is attributed to several key factors: the escalating prevalence of diabetes and obesity, increasing public and medical awareness of metabolic health, and the broader adoption of innovative new therapies, including a growing shift towards oral medications.
The Expanding Role of GLP-1 Agonists
GLP-1 receptor agonists have seen their demand widen sharply beyond initial Type 2 diabetes treatment. Recent studies have highlighted their efficacy in helping patients achieve substantial body weight loss and reducing cardiovascular risks, expanding their therapeutic applications significantly.
Diabetes, Obesity, and Cardiovascular Health
The report from Polaris Market Research indicates that the obesity segment will be the fastest-growing application area for GLP-1 therapies, with a projected CAGR of 55.21% through 2034. Therapies based on semaglutide, such as Novo Nordisk's Ozempic and Wegovy, have demonstrated notable weight reduction outcomes in clinical trials, fueling interest beyond traditional diabetes management. Eli Lilly's Mounjaro and Zepbound are also leading products in this rapidly expanding class.
Oral Therapies Drive Adoption
A major catalyst for market growth is the shift towards oral GLP-1 therapies. The oral delivery segment is projected to grow at a CAGR of 22.9% through 2034, outpacing injectable therapies. This preference for pills over injections stems from the practical and psychological barriers often associated with injectable medications, despite their clinical effectiveness. A significant development in this trend was the US FDA approval in April 2026 of Eli Lilly’s oral GLP-1 drug, orforglipron, branded as Foundayo, marking a crucial step towards more accessible pill-based treatments for diabetes and obesity.
Key Markets and Global Access
While North America currently dominates the GLP-1 market, accounting for a 75.46% revenue share in 2025 due to high healthcare spending and robust insurance coverage, other regions are poised for substantial growth.
Asia Pacific and Emerging Economies
India is identified as a key growth market, facing a rising burden of obesity, diabetes, and lifestyle-linked disorders, particularly within its urban populations. The broader Asia Pacific region, including countries like China, Japan, and Indonesia, is among the fastest-growing for GLP-1 therapies. This growth is driven by urbanization, evolving dietary habits, aging demographics, and increased government investment in chronic disease management infrastructure. Multinational pharmaceutical companies are also actively expanding their presence in these markets.
Further improving access, the World Health Organization's decision in 2025 to add GLP-1 receptor agonists to its Model List of Essential Medicines is expected to benefit lower- and middle-income countries across Asia, Africa, and Latin America.
Industry Leaders and Future Outlook
Key players in the GLP-1 drug market include pharmaceutical giants such as Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, Pfizer, and Amgen. The next phase of growth is anticipated to be shaped by wider insurance coverage for these medications, increasing physician adoption as awareness grows, and the continued launch of newer, more convenient oral therapies.